Market Overview:
The global macular degeneration drug pipeline market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of macular degeneration, rising awareness about available treatments, and technological advancements in the field of gene therapy. The global macular degeneration drug pipeline market is segmented on the basis of type into gene therapy, small molecules, stem cell therapy, and others (including peptides and proteins). The gene therapy segment is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. This growth can be attributed to increasing investments in R&D for novel gene therapies for treating various eye diseases including age-related macular degeneration (AMD) and diabetic retinopathy. On the basis of application, the global macular degeneration drug pipeline market is segmented into hospital use, research institute use, commercial use, and other applications (including veterinary applications). The hospital use segment is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. This growth can be attributedto growing demand for innovative treatments for AMD across hospitals worldwide.
Product Definition:
Macular degeneration is a condition that affects the central part of the retina, called the macula. The macula is responsible for seeing fine details clearly. In people with macular degeneration, this area begins to deteriorate, which can lead to vision loss. There are two main types of macular degeneration: dry and wet.
Dry age-related macular degeneration (AMD) is the most common form of the disease, affecting around 90% of all people with AMD. It occurs when cells in the retina gradually break down and die, causing a gradual loss in central vision. Wet AMD is a more serious form of the disease that develops when abnormal blood vessels grow beneath the retina and leak fluid or blood into its layers.
Gene therapy:
Gene therapy is a new treatment approach that works with the help of gene replacement therapies. The basic principle behind this treatment is to cure the disease by restoring a faulty or damaged gene. This can be done either by replacing the damaged or missing gene with an effective working version of itself, or by removing the function of the harmful protein produced through this particular pathway.
This process involves targeting and repairing genetic defects in cells.
Small molecules:
Small molecules are the chemical compounds that make up a large part of our day to day medications. They can be extracted from nature or created in a laboratory by chemists. Small molecules are used for treating common diseases such as colds, flu, allergies, skin disorders like acne and wrinkles and also some neurological disorders like depression and anxiety.
Application Insights:
The other application segment held the largest share of the global macular degeneration drug pipeline in 2017. This is due to a rise in incidence of AMD and increasing awareness about treatment options among patients. Moreover, presence of key players engaged in research & development activities further propels growth. For instance, Pfizer Inc., one of the major pharmaceutical companies has invested heavily in R&D pertaining to AMD and its pipeline consists of different stages such as gene therapies, small molecules, stem cell therapies and advanced imaging agents for early diagnosis.
In addition to this, many governments have established institutional collaborations with private institutions for conducting clinical trials regarding new drugs or device applications that are aimed at treating Macular Degeneration (AMD).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of companies, which are engaged in various stages of clinical development for macular degeneration treatment. Moreover, increasing R&D investment by major players and government support is expected to drive this regional market over the forecast period. For instance, in September 2018, Research!America received a gift from The Kresge Foundation that will help accelerate research on treatments and therapies for vision loss caused by macular degeneration (AMD).
Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to growing disposable income coupled with rising awareness about early diagnosis among patients suffering from AMD. In addition, high prevalence of diabetes retinopathy among aging population is also expected boost regional growth over next eight years.
Growth Factors:
- Increasing prevalence of macular degeneration: The global prevalence of macular degeneration is expected to increase significantly in the next few years, owing to the aging population. This will create a high demand for macular degeneration drugs and therapies, thereby driving the growth of the Macular Degeneration Drug Pipeline market.
- Technological advancements in drug development: The advancement of technology has led to significant improvements in drug development processes, which is likely to result in the launch of better and more effective drugs for treating macular degeneration. This will spur growth in the Maccular Degeneration Drug Pipeline market over the forecast period.
- Growing awareness about available treatments: There is a growing awareness among people about available treatments for macular degeneration, which is likely to drive demand for these drugs and therapies over the forecast period. This will contribute significantly towards market growth during this period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Macular Degeneration Drug Pipeline Market Research Report
By Type
Gene therapy, Small molecules, Stem cell therapy, Gene therapies
By Application
Hospital, Research Institute, Commercial, Other
By Companies
Amgen, Roche, Adverum Biotechnologies, AsclepiX Therapeutics, Bioeq AG, Sinocelltech, RemeGen, Grifols, S.A., Kyowa Kirin, EyePoint Pharmaceutical, IVERIC Bio, Kodiak Sciences, Ribomic, Lineage Cell Therapeutics, Graybug Vision, CHABiotech, Shanghai Henlius Biotech, Bio-Thera Solutions, Alteogen, Outlook Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
130
Number of Tables & Figures
91
Customization Available
Yes, the report can be customized as per your need.
Global Macular Degeneration Drug Pipeline Market Report Segments:
The global Macular Degeneration Drug Pipeline market is segmented on the basis of:
Types
Gene therapy, Small molecules, Stem cell therapy, Gene therapies
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Research Institute, Commercial, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Roche
- Adverum Biotechnologies
- AsclepiX Therapeutics
- Bioeq AG
- Sinocelltech
- RemeGen
- Grifols, S.A.
- Kyowa Kirin
- EyePoint Pharmaceutical
- IVERIC Bio
- Kodiak Sciences
- Ribomic
- Lineage Cell Therapeutics
- Graybug Vision
- CHABiotech
- Shanghai Henlius Biotech
- Bio-Thera Solutions
- Alteogen
- Outlook Therapeutics
Highlights of The Macular Degeneration Drug Pipeline Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Gene therapy
- Small molecules
- Stem cell therapy
- Gene therapies
- By Application:
- Hospital
- Research Institute
- Commercial
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Macular Degeneration Drug Pipeline Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
The Macular Degeneration Drug Pipeline consists of drugs and drug candidates that are being developed to treat macular degeneration.
Some of the major players in the macular degeneration drug pipeline market are Amgen, Roche, Adverum Biotechnologies, AsclepiX Therapeutics, Bioeq AG, Sinocelltech, RemeGen, Grifols, S.A., Kyowa Kirin, EyePoint Pharmaceutical, IVERIC Bio, Kodiak Sciences, Ribomic, Lineage Cell Therapeutics, Graybug Vision, CHABiotech, Shanghai Henlius Biotech, Bio-Thera Solutions, Alteogen, Outlook Therapeutics.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Macular Degeneration Drug Pipeline Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Macular Degeneration Drug Pipeline Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Macular Degeneration Drug Pipeline Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Macular Degeneration Drug Pipeline Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Macular Degeneration Drug Pipeline Market Size & Forecast, 2018-2028
4.5.1 Macular Degeneration Drug Pipeline Market Size and Y-o-Y Growth
4.5.2 Macular Degeneration Drug Pipeline Market Absolute $ Opportunity
Chapter 5 Global Macular Degeneration Drug Pipeline Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Macular Degeneration Drug Pipeline Market Size Forecast by Type
5.2.1 Gene therapy
5.2.2 Small molecules
5.2.3 Stem cell therapy
5.2.4 Gene therapies
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Macular Degeneration Drug Pipeline Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Macular Degeneration Drug Pipeline Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Research Institute
6.2.3 Commercial
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Macular Degeneration Drug Pipeline Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Macular Degeneration Drug Pipeline Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Macular Degeneration Drug Pipeline Analysis and Forecast
9.1 Introduction
9.2 North America Macular Degeneration Drug Pipeline Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Macular Degeneration Drug Pipeline Market Size Forecast by Type
9.6.1 Gene therapy
9.6.2 Small molecules
9.6.3 Stem cell therapy
9.6.4 Gene therapies
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Macular Degeneration Drug Pipeline Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Research Institute
9.10.3 Commercial
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Macular Degeneration Drug Pipeline Analysis and Forecast
10.1 Introduction
10.2 Europe Macular Degeneration Drug Pipeline Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Macular Degeneration Drug Pipeline Market Size Forecast by Type
10.6.1 Gene therapy
10.6.2 Small molecules
10.6.3 Stem cell therapy
10.6.4 Gene therapies
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Macular Degeneration Drug Pipeline Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Research Institute
10.10.3 Commercial
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Macular Degeneration Drug Pipeline Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Macular Degeneration Drug Pipeline Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Macular Degeneration Drug Pipeline Market Size Forecast by Type
11.6.1 Gene therapy
11.6.2 Small molecules
11.6.3 Stem cell therapy
11.6.4 Gene therapies
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Macular Degeneration Drug Pipeline Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Research Institute
11.10.3 Commercial
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Macular Degeneration Drug Pipeline Analysis and Forecast
12.1 Introduction
12.2 Latin America Macular Degeneration Drug Pipeline Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Macular Degeneration Drug Pipeline Market Size Forecast by Type
12.6.1 Gene therapy
12.6.2 Small molecules
12.6.3 Stem cell therapy
12.6.4 Gene therapies
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Macular Degeneration Drug Pipeline Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Research Institute
12.10.3 Commercial
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Macular Degeneration Drug Pipeline Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Macular Degeneration Drug Pipeline Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Macular Degeneration Drug Pipeline Market Size Forecast by Type
13.6.1 Gene therapy
13.6.2 Small molecules
13.6.3 Stem cell therapy
13.6.4 Gene therapies
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Macular Degeneration Drug Pipeline Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Research Institute
13.10.3 Commercial
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Macular Degeneration Drug Pipeline Market: Competitive Dashboard
14.2 Global Macular Degeneration Drug Pipeline Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Roche
14.3.3 Adverum Biotechnologies
14.3.4 AsclepiX Therapeutics
14.3.5 Bioeq AG
14.3.6 Sinocelltech
14.3.7 RemeGen
14.3.8 Grifols, S.A.
14.3.9 Kyowa Kirin
14.3.10 EyePoint Pharmaceutical
14.3.11 IVERIC Bio
14.3.12 Kodiak Sciences
14.3.13 Ribomic
14.3.14 Lineage Cell Therapeutics
14.3.15 Graybug Vision
14.3.16 CHABiotech
14.3.17 Shanghai Henlius Biotech
14.3.18 Bio-Thera Solutions
14.3.19 Alteogen
14.3.20 Outlook Therapeutics
